NSABP MEMBER--MICHIGAN STATE UNIVERSITY

这项研究建议是乳腺癌初级治疗的一部分 集团-NSABP。NSABP的主要目标是提高无病 一期可手术乳腺癌患者的存活率和总存活率 结直肠癌(见NSABP总部拨款申请 议定书的基本原理和总体科学成就)。密歇根州立大学 大学自1976年以来一直是NSABP的成员。在前十个月 多年来，这些卫星、校园在密歇根州形成了强大的 以主校区为核心的联合体。目前，我们 正在治疗和跟踪953名长期服用NSABP佐剂的患者 协议。我们希望将每名患者的应计收入增加到160(30%) 年，将大幅增加随访患者的数量 在接下来的五年里。五位新的肿瘤学家接受了临床培训 选拔赛加入了我们的社区校园。他们将为 增加应计利润。我们的外展计划一直是一个重要的 过去几年NSABP临床试验的贡献者。 除了我们努力让患者接受NSABP方案外，我们的成员 作为主席积极参加该小组的科学活动 乳腺癌诊断和治疗生物制品委员会， 结肠癌委员会，并组织和计划小组科学计划。这个 PI积极参与了先导研究的设计。拥有一个 配备了高效液相、气相色谱和质谱学的先进实验室 仪器，我们机构将为该小组提供额外的学习 与药物和激素代谢物有关。我们已经并将继续 积极参加小组会议。私家侦探一直在 集团过去五年的执行委员会，以及 在过去的六年里，护理委员会的护士们。我们是 为集团的审计计划做出贡献，两名护士被分配到 审计团队。 三名医生参与了最近出版的手稿 以及提交给ASCO会议的摘要。我们打算增加这一比例 活动。PI积极参与了许多NCI的现场访问 和同行评议委员会。 我们的机构有一个特殊的计划来促进和监测 少数民族到NSABP受审。我们有一个独特的组织来 基于学术界的NSABP试验的产生和执行 联盟(社区校园)和PI承担所有责任 与团队努力相关的活动。

This research proposal is a part of the Primary Breast Cancer Therapy Group - NSABP. The main objective of the NSABP is to improve disease-free survival and overall survival in patients with primary operable breast and colo-rectal cancer (See the NSABP Headquarters Grant application for protocol rationale and overall scientific achievements). Michigan State University has been a member of NSABP since 1976. During the first ten years, the satellites, campuses in the state of Michigan, formed a strong consortium with the nucleus at the main campus. At the present time, we are treating and following 953 patients on long-term NSABP adjuvant protocols. We expect to increase our accrual to 160 (30%) patients per year which will increase substantially the number of follow-up patients during the next five years. Five new oncologists trained in clinical trials joined our community campuses. They will contribute to the increase of the accrual. Our outreach program has been a major contributor to NSABP clinical trials during the last years. Besides our efforts to accrue patients to NSABP protocols, our members participated actively in the scientific activities of the group as chair of the Committee of Biologics in Diagnosis and Treatment of Breast Cancer, Colon Committee, and organized and planned group scientific programs. The PI participates actively in the design of the pilot studies. Having a well developed laboratory equipped with HPLC, GLC and Mass Spectroscopy apparatuses, our institution will offer to the group additional studies related to drug and hormone metabolites. We have and will continue to participate actively in the group meetings. The PI has been on the executive committee of the group for the last five years and one of the nurses on the Nursing Committee for the last six years. We are contributing to the Audit Program of the group with two nurses assigned to auditing teams. Three physicians have participated in recent publications of manuscripts and abstracts presented to ASCO meetings. We intend to increase this activity. The PI has actively participated in numerous NCI site visits and peer review committees. Our institution has a special program to foster and monitor accrual of ethnic minorities to NSABP trials. We have a unique organization for accrual and execution of NSABP trials based on academic community consortium (community campuses) and the PI assumes responsibility for all activities related to the group efforts.